A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

  • Respiratory Disorder
  • Idiopathic Pulmonary Fibrosis
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • Boston
  • Elk Grove Village
  • Everett
  • Greensboro
  • Hannover
  • Louisville
  • Muncie
  • New Orleans
  • Omaha
  • Orlando
  • Reno
  • San Diego
  • Seattle
  • Summit
  • Wilmington
Trial Identifier:

NCT02648048 2015-003481-81 GB29764

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT02648048,GB29764,2015-003481-81 Trial Identifier
      Pirfenidone, Vismodegib Treatments
      Idiopathic Pulmonary Fibrosis Condition
      Official Title

      A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

      Eligibility criteria

      All Gender
      ≥ 40 Years & ≤ 80 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Have a diagnosis of IPF 5 years from time of screening, confirmed at baseline
      • Tolerated dose of pirfenidone 1602-2403 mg once daily (QD) for a minimum of 24 weeks required prior to and during screening
      • Greater than or equal to (>=) 50 percent (%) and less than or equal to (<=) 100% of predicted forced vital capacity (FVC) at screening
      • Stable baseline lung function as evidenced by a difference of less than (<) 10% in absolute FVC measurements (in liters) between screening and Day 1/Visit 2 prior to enrollment
      • >=30% and <=90% of predicted diffusion capacity of the lung for carbon monoxide at screening
      • Agree to use protocol defined methods of contraception
      • Male participants must agree not to donate semen during the study and for at least 2 months (or as per local requirements) after the last dose of vismodegib
      • Agree not to donate blood or blood products during the study and for at least 9 months (or as per local requirements) after the last dose of study treatment
      Exclusion Criteria
      • Prior treatment with vismodegib or any Hh-pathway inhibitor
      • Evidence of other known causes of interstitial lung disease
      • Hospitalization due to an exacerbation of IPF within 4 weeks prior to or during screening
      • Lung transplant expected within 6 months of screening
      • Evidence of clinically significant lung disease other than IPF
      • Post-bronchodilator forced expiratory volume in 1 second/FVC ratio <0.7 at screening
      • Any clinically significant medical disease (other than IPF) that is associated with an expected survival of <6 months, likely to require a change in therapy during the study
      • Class IV New York Heart Association chronic heart failure or historical evidence of left ventricular ejection fraction <35%
      • Known current malignancy or current evaluation for a potential malignancy
      • Known immunodeficiency, including, but not limited to, human immunodeficiency virus infection
      • Evidence of acute or chronic hepatitis or known liver cirrhosis
      • Creatinine clearance <=30 milliliter per minute, calculated using the Cockcroft-Gault formula

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now